Christopher Peetz - 07 Jan 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Reporting relationship
CHIEF EXECUTIVE OFFICER, Director
Issuer ticker
MIRM
Reported as of
07 Jan 2025
Net transaction value
-$320,644
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
08 Jan 2025, 16:42:49 UTC
Prior SEC filing
14 Nov 2024
Next SEC filing
23 Jan 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Judit Ryvkin, Attorney-in-Fact

Key filing fact

Christopher Peetz filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 08 Jan 2025.

Key facts

  • This page summarizes Christopher Peetz's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 08 Jan 2025, 16:42.

Change

  • Previous filing in this sequence was filed on 14 Nov 2024.
  • Current net transaction value: -$320,644.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRM transaction

Common Stock

Sale

Transaction value
$320,644
Shares
-7,489
Change %
-5.9%
Price
$42.82
Shares after
119,359
Date
07 Jan 2025
Ownership
Direct
Footnotes
F1
MIRM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
208,570
Date
07 Jan 2025
Ownership
By The Peetz Family Trust
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .